Related references
Note: Only part of the references are listed.Drotrecogin Alfa (Activated) in Adults with Septic Shock
V. Marco Ranieri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Activated protein C in septic shock: a propensity-matched analysis
Farid Sadaka et al.
CRITICAL CARE (2011)
Activated protein C and hospital mortality in septic shock: A propensity-matched analysis
Peter K. Lindenauer et al.
CRITICAL CARE MEDICINE (2010)
Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: A propensity-matched analysis
Anand Kumar et al.
CRITICAL CARE MEDICINE (2010)
Back to belief-based medicine because of receiver operating characteristic curves? Reply
Ryan Zarychanski et al.
CRITICAL CARE MEDICINE (2009)
Early intravenous unfractionated heparin and mortality in septic shock
Ryan Zarychanski et al.
CRITICAL CARE MEDICINE (2008)
A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003
Peter C. Austin
STATISTICS IN MEDICINE (2008)
Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial
Simon Nadel et al.
LANCET (2007)
Immortal time bias in observational studies of drug effects
Samy Suissa
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study
Salmaan Kanji et al.
INTENSIVE CARE MEDICINE (2007)
Variable selection for propensity score models
M. Alan Brookhart et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2006)
Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock
Arland Kumar et al.
CRITICAL CARE MEDICINE (2006)
Indications for propensity scores and review of their use in pharmacoepidemiology
RJ Glynn et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2006)
Propensity scores - An introduction and experimental test
JK Luellen et al.
EVALUATION REVIEW (2005)
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death
E Abraham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Use of intensive care at the end of life in the United States: An epidemiologic study
DC Angus et al.
CRITICAL CARE MEDICINE (2004)
Medical progress: The pathophysiology and treatment of sepsis.
RS Hotchkiss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
DC Angus et al.
CRITICAL CARE MEDICINE (2001)
Efficacy and safety of recombinant human activated protein C for severe sepsis.
GR Bernard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)